In order to further analyze the changes in the field of new drugs in the world, the author analyzed 16 major therapeutic areas of the Pharmaprojects database, and then divided the drugs in 16 therapeutic fields into 232 treatment categories, and classified them into 1350 diseases or adaptations. disease. Comparing the data of 2017 and 2016, and analyzing the changes in the number of drugs in different treatment categories, all No. 1 is a category of anticancer drugs.
The author analyzed the drug in the 16 major therapeutic areas of the Pharmaprojects database and the biotechnology category. In addition to the respiratory system, the number of new drugs in each therapeutic field increased in 2017.
On the whole, anticancer drugs, biotechnology drugs, nervous system drugs, anti-infective drugs and digestive/metabolizing drugs rank among the top 5 therapeutic areas.
Among them, cancer is still the core area of ​​drug research and development, and the number of anti-cancer/anti-tumor drugs has increased significantly. The number has increased from 4,176 in 2016 to 4,845, and the number of drug candidates has increased by 669, an increase of 16.0%. This growth rate broke the 15.9% history created in 2016 and far exceeded the average growth rate of the 8.0% pharmaceutical R&D industry. In terms of the proportion, almost one-third (32.6%) of the research targets for research and development are tumor diseases.
In addition, treatment areas with growth rates exceeding the industry's average growth rate include anti-infectives (up 11.1%), biotech drugs (10.6%), sensory drugs (9.9%), and dermatological drugs (9). .6%) and hormone drugs (8.3%).
On the other hand, the number of drugs under investigation in some therapeutic areas has declined. For example, the number of respiratory drugs in 2017 decreased by 1.2% year-on-year. The increase in the number of drugs under investigation in some therapeutic areas has slowed down. For example, in 2017, the increase of neurological drugs was only 1.2%, the cardiovascular system drug increased by 1.3%, and the musculoskeletal drug increased by 5.0%. Compared with the increase in previous years, the growth of these categories of drugs is relatively limited.
Judging from the available statistics, although anti-cancer/anti-tumor drugs have not yet occupied the absolute dominant position in the research and development of new drugs, their numbers have shown an increasing trend year by year and should be given special attention.
Subdividing the drugs in 16 therapeutic areas into 232 treatment categories, which can be compared with the 2016 data, reflecting the changes in the number of drugs being studied in different treatment categories.
Modified soybean phospholipid refers to a type of phospholipid that has been altered or processed in some way to improve its functionality or suitability for various applications. This can include changes to the chemical composition, molecular structure, or physical properties of the phospholipid.
Modified Soybean Pholipid,Modified Soybean Lecithin Oil,Modified Soy Lecithin Oil,Modified Soy Lecithin
Jiangsu Chenwei Biology and Technology Co. LTD , https://www.cwsoybean.com